Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.

Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study.

Background: The impact of early-stage chronic kidney disease (CKD) on cardiovascular outcomes, particularly when albuminuria is present, remains unclear. This study examined the associations between early CKD (stages 1 and 2) with and without albuminuria and the incidence of major adverse cardiovascular events (MACEs), heart failure (HF) and all-cause mortality.

Methods: A cohort of 456 015 participants from the UK Biobank was categorised by CKD stage using serum creatinine to calculate estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (≥3 mg/mmol) to define albuminuria.

A consensus on the definition of positive animal welfare.

The concept of animal welfare is evolving due to progress in our scientific understanding of animal biology and changing societal expectations. Animal welfare science has been primarily concerned with minimizing suffering, but there is growing interest in also promoting positive experiences, grouped under the term positive animal welfare (PAW). However, there are discrepancies in the use of the term PAW.

Allergens Responsible for Contact Allergy in Children From 2010 to 2024: A Systematic Review and Meta-Analysis.

Contact allergy (CA) is a frequent condition in children; however, newer estimates of the prevalence of CA in children are lacking. Herein, we aim to provide an estimate of the prevalence of CA in children from 2010 to 2024. Two authors independently searched PubMed, Embase and Web of Science for studies reporting the prevalence of positive patch tests (PPTs) to allergens in populations including ≥ 100 children (< 18 years).